C50
Conditions
Interventions
Group 1: Retrospective study of 1) gene expression data of >900 breast cancer patients available from the TCGA (The Cancer Genome Atlas) and 2) of formalin fixed paraffin embedded tumor samples of pat
Sponsors
Medizinische Universität Graz
Klinische Abteilung für Onkologie
Universitätsklinik für Innere Medizin
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patient specimens are selected based on the results of the analysis of the TCGA: Primary start date: 1.1.1990 Consecutive Patients with a) documented follow up including type of therapy of at least 5 years b) no primary distant metastases at primary diagnosis c) fulfilling one of the following criteria i) ER+, PgR+/-, HER2- ii) ER+, PgR+/-, HER2+ Number of positive lymph nodes, age, tumor type, tumor grade, accompanying in situ neoplasia, received or non-received radiation therapy will be no selection criterion, but will be evaluated in sub analyses.
Exclusion criteria
Exclusion criteria: in case inclusion criteria are not fullfilled
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of GIRK /G-protein activated inwardly rectifying potassium channels) Expression profiles with disease free survival (DFS) and overall survival (OS) in patients with primary operated breast cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of GIRK (G-protein activated inwardly rectifying potassium channels) expression profiles with a.) pathological subtypes of breast cancer b.) tumor stage c.) pathological characteristics of the primary tumor (hormone receptor expression, Her2/neu status, KI67 proliferation index) d.) type of metastatic spread e) treatment outcome | — |
Countries
Austria
Contacts
Public ContactThomas Bauernhofer
Medizinische Universität Graz Klinische Abteilung für Klinische Onkologie Universitätsklinik für Innere Medizin
Outcome results
None listed